MedTrace Logo

Omega-3, Autism Spectrum Disorder (ASD)

NCT07365553 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-01-26

No results posted yet for this study

Summary

This is a 12 week study to investigate the effects of omega-3 polyunsaturated fatty acids (PUFAs) in youth with autism spectrum disorder (ASD).

Conditions

  • ASD

Interventions

DIETARY_SUPPLEMENT

Omega-3

Omega-3 PUFAs

DIETARY_SUPPLEMENT

Placebo

Soybean Oil

Sponsors & Collaborators

  • China Medical University Hospital

    lead OTHER

Principal Investigators

  • Pei-Chen Chang, MD, PhD · China Medical University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-15
Primary Completion
2026-06-30
Completion
2026-07-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07365553 on ClinicalTrials.gov